OncoMatch/Clinical Trials/NCT05014464
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Is NCT05014464 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Crizotinib for non-small cell lung cancer.
Treatment: Crizotinib — This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK fusion
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EGFR antibody
Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug
Cannot have received: VEGFR antibody
Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug
Cannot have received: radiation therapy
Exception: Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose
Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity
Lab requirements
Blood counts
adequate bone marrow hematopoiesis
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate bone marrow hematopoiesis and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify